Immunotherapy Focus ITB-MED is developing TCD601 (siplizumab), a CD2-directed monoclonal antibody aimed at transplantation and autoimmunity, signaling opportunities to partner on immunomodulatory therapies, companion diagnostics, and clinical trial collaboration with larger pharma.

Clinical Expansion Active pursuit of worldwide clinical trials suggests potential collaboration in international sites, CROs, and regulatory strategy services to accelerate global enrollment and non-dilutive financing options through multi-region studies.

Funding & Scale A substantial prior financing round ($67M) and revenue in the low single digits indicate readiness for co-development, licensing deals, or strategic investments to advance later-stage development and commercialization readiness.

Transplant Opportunity Recent press highlights position ITB-MED as pursuing organ transplant immunosuppression alternatives, creating a clear come-on for partnerships with transplant centers, immunology-focused CROs, and pharma players targeting post-transplant therapies.

Tech & Operations Utilization of modern cloud and collaboration tools (Azure, Microsoft 365, OpenAI, Dropbox, Shopify) signals a digitally mature startup posture compatible with scalable data management, eClinical collaboration platforms, and partner integration workflows.